Essure: More Dangerous Than Alternatives or Simply a Failure to Communicate Risks?
By Zuzanna Fiminska Précis: There’s been something of a public backlash against Bayer’s permanent…
Year in Review 2013: Evidence and Market Access
Précis: 2013 is the year transparency became ‘a thing’, and quite a serious…